drugset / Trial / NCT05918133
A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC
NaSingle-groupOpen-labelTreatment
Summary
Here, the investigators present the results from a Phase Ib/II study of PM8002 in combination with nab-paclitaxel in subjects with locally advanced or metastatic triple negative breast cancer without previous systematic treatment.
Timeline
- Start
- 2022-07-01
- Primary completion
- 2026-10-30
- Completion
- 2026-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paclitaxel | Small molecule | 100 mg/m2 | Intravenous |
| Subject | Pumitamig | Protein / enzyme biologic | 20 mg/kg | Intravenous |